The clinical risk grouping solution market had an estimated market share worth US$ 526.2 million in 2023, and it is predicted to reach a global market valuation of US$ 2380 million by 2034, growing at a steady CAGR of 14.7% from 2024 to 2034.
The growing emphasis on social determinants of health (SDOH) is emerging as a market driver in clinical risk grouping solutions. Integrating SDOH information into risk stratification models allows healthcare professionals to address socioeconomic variables that influence patient health. This results in more thorough risk assessments and personalized treatments to promote health equality and outcomes.
Demand Analysis of Clinical Risk Grouping Solution
| Report Attribute | Details |
|---|---|
| Estimated Market Value in 2023 | US$ 526.2 million |
| Expected Market Value in 2024 | US$ 605.7 million |
| Projected Forecast Value in 2034 | US$ 2,380 million |
| Anticipated Growth Rate from 2024 to 2034 | 1 4.7% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for the clinical risk grouping solution market was estimated to reach a valuation of US$ 290 million in 2019, according to a report from Future Market Insights (FMI). From 2019 to 2023, sales witnessed significant growth in the clinical risk grouping solution market, registering a CAGR of 16.1%.
| Historical CAGR from 2019 to 2023 | 16.1% |
|---|---|
| Forecast CAGR from2024 to 2034 | 14.7% |
The need for clinical risk grouping solutions is driven by the expansion of healthcare accessibility. Effective risk assessment and classification techniques are necessary to increase patient participation.
By enabling focused treatments and individualized care plans, these solutions promote better health outcomes. Some important factors that will boost the market growth through 2034 are:
Growing Incidence of Chronic illnesses globally to boost Demand
The growing incidence of chronic illnesses globally is another factor propelling the market for clinical risk grouping solutions. As the prevalence of chronic illnesses like diabetes, heart disease, and cancer rises, healthcare institutions are looking for better ways to handle these complicated medical disorders.
Clinical risk grouping solutions provide a proactive approach. This is done by identifying high-risk patient categories, allowing for early intervention, tailored treatment plans, and preventative actions to slow the course and consequences of chronic illnesses, hence improving patient outcomes.
Focus on Value Based Care Models to bolster Demand Globally
A factor propelling the market for clinical risk grouping solutions is the growing emphasis on value-based care models. Reimbursement models for healthcare organizations are shifting from fee-for-service to value-based, which encourages the use of risk grouping strategies to save costs and enhance patient outcomes.
Healthcare practitioners may better focus interventions, allocate resources more efficiently, and improve care delivery by stratifying patients based on their risk profiles. This approach is in line with the objectives of value-based care efforts.
Principal Consultant
Interoperability Challenges within Healthcare IT Systems to Stifle the Market Growth
There are a number of constraints impeding the growth of the clinical risk grouping solutions market, such as interoperability issues in healthcare IT systems that make data exchange and integration difficult.
Adoption is further hampered by worries about data security and privacy, particularly in light of the delicate nature of patient health information. Slower acceptance rates among healthcare providers and organizations are a result of a lack of knowledge and comprehension of the advantages of risk grouping solutions, which restrains market growth.
This section focuses on providing detailed analysis of two particular market segments for clinical risk grouping solutions, the dominant product type and the significant deployment type. The two main segments discussed below are data visualization tools and private cloud.
| Product | Data Visualization Tools |
|---|---|
| CAGR from 2024 to 2034 | 14.6% |
During the forecast period, the data visualization tools segment is likely to garner a 14.6% CAGR. Data visualization tools are likely to gain momentum in the clinical risk grouping solution market because of their ability to transform complicated data into meaningful insights.
With the growing volume and complexity of healthcare data, visualization technologies provide accessible and interactive interfaces that allow healthcare workers to quickly evaluate and share critical results.
By enabling companies to recognize patterns, trends, and risk factors more successfully, these solutions support data-driven decision-making and enhance patient outcomes as well as operational effectiveness.
| Deployment Type | Private Cloud |
|---|---|
| Market Share in 2024 | 50.9% |
In 2024, the private cloud segment is likely to acquire a 50.9% global market share. Due to improved security, compliance, and control, companies are moving more and more toward private cloud deployment for products like clinical risk grouping. For sensitive healthcare data, private clouds provide specialized infrastructure that guarantees data privacy and regulatory compliance.
They also give enterprises more flexibility and control over resources, enabling them to customize deployments to meet their unique requirements. Private clouds meet the expanding need for adaptable and durable healthcare IT systems by providing scalability and stability.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The markets for clinical risk grouping solutions in a few significant countries, including the United States, the United Kingdom, China, Japan, and South Korea, will be covered in detail in this section. This section will concentrate on the major variables that are increasing the demand in these nations for clinical risk grouping solutions.
| Countries | CAGR |
|---|---|
| The United States | 7.5% |
| The United Kingdom | 8.3% |
| China | 7.8% |
| Japan | 8.8% |
| South Korea | 9.3% |
The United States clinical risk grouping solution is anticipated to gain a CAGR of 14.8% through 2034. Factors that are bolstering the growth are:
The market in the United Kingdom is expected to expand with a 15.7% CAGR through 2034. The factors pushing the growth are:
The clinical risk grouping solution ecosystem in China is anticipated to develop with a 15% CAGR from 2024 to 2034. The drivers behind this growth are:
The clinical risk grouping solution industry in Japan is anticipated to reach a 15.9% CAGR from 2024 to 2034. The drivers propelling growth forward are:
The clinical risk grouping solution ecosystem in South Korea is likely to evolve with a 17.2% CAGR during the forecast period. The factors bolstering the growth are:
Leading companies in the global market for clinical risk grouping solutions are creating extensive risk assessment tools by utilizing machine learning algorithms and advanced data analytics. By classifying patient populations according to their risk profiles, these tools help healthcare practitioners create individualized care plans and focused treatments.
Important firms are also concentrating on integration skills and interoperability to guarantee a smooth integration with the current healthcare IT infrastructure. The use of clinical risk grouping solutions is further enhanced by strategic alliances and collaborations with healthcare organizations, which propel market growth and innovation throughout healthcare risk management. The key players in this market include:
Significant advancements in the clinical risk grouping solution sector are being made by key market participants, and these include:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 14.7% from 2024 to 2034 |
| Market Value in 2024 | US$ 605.7 million |
| Market Value in 2034 | US$ 2,380 million |
| Base Year for Estimation | 2023 |
| Historical Data | 2019 to 2023 |
| Forecast Period | 2024 to 2034 |
| Quantitative Units | US$ million for value |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Countries Profiled |
|
| Key Companies Profiled |
|
| Customization Scope | Available on Request |
The clinical risk grouping solution market is expected to garner a 14.7% CAGR from 2024 to 2034.
By 2024, the global clinical risk grouping solution market is likely to gain US$ 605.7 million.
By 2034, the clinical risk grouping solution market valuation is likely to reach a sum of US$ 2380 million.
The clinical risk grouping solution industry in the United States is likely to garner a 14.8% CAGR during the forecast period.
The data visualization tools will gain immense popularity and evolve with a 14.6% CAGR through 2034.
The private cloud segment by deployment type is likely to garner a 14.5% CAGR through 2034.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Product, 2019 to 2023 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product, 2024 to 2034 5.3.1. Data Visualization Tools 5.3.1.1. Software 5.3.1.2. Services 5.3.2. Data Analytics 5.4. Y-o-Y Growth Trend Analysis By Product, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Product, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Deployment 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Deployment, 2019 to 2023 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Deployment, 2024 to 2034 6.3.1. Private Cloud 6.3.2. Public Cloud 6.3.3. Hybrid Cloud 6.4. Y-o-Y Growth Trend Analysis By Deployment, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Deployment, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2019 to 2023 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2024 to 2034 7.3.1. Healthcare Service Providers 7.3.2. Helthcare Payers 7.4. Y-o-Y Growth Trend Analysis By End User, 2019 to 2023 7.5. Absolute $ Opportunity Analysis By End User, 2024 to 2034 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Product 9.2.3. By Deployment 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product 9.3.3. By Deployment 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Product 10.2.3. By Deployment 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product 10.3.3. By Deployment 10.3.4. By End User 10.4. Key Takeaways 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Product 11.2.3. By Deployment 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product 11.3.3. By Deployment 11.3.4. By End User 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Product 12.2.3. By Deployment 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product 12.3.3. By Deployment 12.3.4. By End User 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Product 13.2.3. By Deployment 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product 13.3.3. By Deployment 13.3.4. By End User 13.4. Key Takeaways 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Product 14.2.3. By Deployment 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product 14.3.3. By Deployment 14.3.4. By End User 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Product 15.2.3. By Deployment 15.2.4. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Product 15.3.3. By Deployment 15.3.4. By End User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2023 16.1.2.1. By Product 16.1.2.2. By Deployment 16.1.2.3. By End User 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2023 16.2.2.1. By Product 16.2.2.2. By Deployment 16.2.2.3. By End User 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2023 16.3.2.1. By Product 16.3.2.2. By Deployment 16.3.2.3. By End User 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2023 16.4.2.1. By Product 16.4.2.2. By Deployment 16.4.2.3. By End User 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2023 16.5.2.1. By Product 16.5.2.2. By Deployment 16.5.2.3. By End User 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2023 16.6.2.1. By Product 16.6.2.2. By Deployment 16.6.2.3. By End User 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2023 16.7.2.1. By Product 16.7.2.2. By Deployment 16.7.2.3. By End User 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2023 16.8.2.1. By Product 16.8.2.2. By Deployment 16.8.2.3. By End User 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2023 16.9.2.1. By Product 16.9.2.2. By Deployment 16.9.2.3. By End User 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2023 16.10.2.1. By Product 16.10.2.2. By Deployment 16.10.2.3. By End User 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2023 16.11.2.1. By Product 16.11.2.2. By Deployment 16.11.2.3. By End User 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2023 16.12.2.1. By Product 16.12.2.2. By Deployment 16.12.2.3. By End User 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2023 16.13.2.1. By Product 16.13.2.2. By Deployment 16.13.2.3. By End User 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2023 16.14.2.1. By Product 16.14.2.2. By Deployment 16.14.2.3. By End User 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2023 16.15.2.1. By Product 16.15.2.2. By Deployment 16.15.2.3. By End User 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2023 16.16.2.1. By Product 16.16.2.2. By Deployment 16.16.2.3. By End User 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2023 16.17.2.1. By Product 16.17.2.2. By Deployment 16.17.2.3. By End User 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2023 16.18.2.1. By Product 16.18.2.2. By Deployment 16.18.2.3. By End User 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2023 16.19.2.1. By Product 16.19.2.2. By Deployment 16.19.2.3. By End User 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2023 16.20.2.1. By Product 16.20.2.2. By Deployment 16.20.2.3. By End User 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2023 16.21.2.1. By Product 16.21.2.2. By Deployment 16.21.2.3. By End User 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2023 16.22.2.1. By Product 16.22.2.2. By Deployment 16.22.2.3. By End User 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2023 16.23.2.1. By Product 16.23.2.2. By Deployment 16.23.2.3. By End User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Product 17.3.3. By Deployment 17.3.4. By End User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Conduent Inc 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. HBI Solutions 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. 3M Corporation 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Cerner Corporation 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Optum, Inc 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Dynamic Healthcare Systems 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Nuance Communications 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Lightbeam Health Solutions 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Health Catalyst, Inc 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Johns Hopkins University 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Healthcare
June 2024
REP-GB-14775
250 pages
Explore Healthcare Insights
View Reports
Clinical Risk Grouping Solution Market
